Guidelines for the management of inflammatory bowel disease in adults

Gut

Volumn 53, Issue SUPPL. 5, 2004, Pages

  Carter, M J ^a   Lobo, A J ^a   Travis, S P L ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BALSALAZIDE; BENZOIC ACID DERIVATIVE; BETAMETHASONE; BUDESONIDE; CALCINEURIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; DIVISTYRAMINE; HEPARIN; HETEROCYCLIC COMPOUND; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; MESREN; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TIOGUANINE;

ACNE; ADRENAL INSUFFICIENCY; ADULT; AGRANULOCYTOSIS; ANAMNESIS; ANAPHYLAXIS; ARTHRALGIA; BONE NECROSIS; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DIET THERAPY; DISEASE MARKER; DRUG HYPERSENSITIVITY; DYSPEPSIA; EDEMA; ENTERITIS; EPIGASTRIC PAIN; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; HEADACHE; HEALTH CARE DELIVERY; HEART FAILURE; HIRSUTISM; HISTOPATHOLOGY; HUMAN; INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; LUNG ALVEOLITIS; MALAISE; MEDICAL AUDIT; META ANALYSIS; MOOD DISORDER; MOON FACE; MYALGIA; MYOPATHY; NAUSEA; NEPHROTIC SYNDROME; NEUROTOXICITY; NUTRITION; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PATIENT ATTITUDE; PATIENT SATISFACTION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REMISSION; REVIEW; SEIZURE; SIGMOIDOSCOPY; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; STOMATITIS; TREMOR; TUBERCULOSIS; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 4344602852     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.043372     Document Type: Review

References (152)

1. Eccles M, Clapp Z, Grimshaw J, et al. North of England evidence based guidelines development project methods of guideline development. BMJ 1996;312:760-2.
2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
3. Longobardi T, Jacobs T, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a national population health survey. Am J Gastroenterol 2003;98:844-9.
4. Card T, Hubbard R, Logan RFA. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 2003;125:1583-90.
5. Robinson A, Thompson DG, Wilkin D, et al. Guided self-management and practice-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001;358:976-81.
6. Shivananda S, Lennard-Jones JE, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996;39:690-7.
7. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004;126:1518-32.
8. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
9. Lapidus A, Bernell O, Hellers G, et al. Incidence of Crohn's disease in Stockholm county 1955-1989. Gut 1997;41:480-6.
10. Rubin GP, Hungin AP, Kelly PJ, et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553-9.
11. Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 2002;252:475-96.
12. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706
13. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
14. Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;105:1716-23.
15. Lennard-Jones JE, Shivananda S and the EC-IBD Study Group. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. Eur J Gastroenterol & Hepatol 1997;9:353-9.
16. Winther K, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125:1576-82.
17. Sandborn WJ, Feagan BG, Hanauer SB, et al. Review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30.
18. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955;ii:1041-8.
19. Walmsley RS, Ayres RCS, Pounder RE, et al. A simple clinical colitis index. Gut 1998;43:29-32.
20. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Path 1997;50:93-105.
21. Scotiniotis I, Rubesin SE, Ginsberg G. Imaging modalities in inflammatory bowel disease. Gastroenterol Clin N Am 1999;28:391-421.
22. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine prodrugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29-42.
23. Sutherland LR, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev 2002;(4):CD000544.
24. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-53.
25. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88.
26. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of post-operative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118:264-273.
27. Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996;108:688-93.
28. Sutherland L, Roth D, Beck, et al. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000;(2):CD000543.
29. Feagan BG. 5-ASA therapy for active Crohn's disease: old friends, old data and a new conclusion. Clin Gastroenterol Hepatol 2004;2:376-8.
30. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized multicenter trial. Gastroenterology 1999;116:521-6.
31. Summers RW, Switz DM, Sessions JT, et al. National co-operative Crohn's disease study group: results of drug treatment. Gastroenterology 1979;77:847-69.
32. Loftus EV, Kane SV, Bjorkman D. Systemic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-89.
33. Ransford RAJ, Langman MJS. Sulphasolazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-39.
34. van Staa TP, Travis SPL, Leufkens HJM, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiological study. Gastroenterology 2004;126:1733-9.
35. Franchimont D, Kino T, Galon J, et al. Glucorticoids and inflammation revisited: the state of the art. Neuroimmunomodulation 2003;10:247-60.
36. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2001;(3):CD000301.
37. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and SASP therapy in ulcerative colitis. BMJ 1962;2:1708-11.
38. Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, Salazopyrin and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960;1:217-22.
39. Baron JH, Connell AM, Kanaghinis TG, et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. BMJ 1962;2:441-3.
40. Malchow H, Ewe K, Brandes JW, et al. European co-operative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
41. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-18.
42. Kane SV, Schoenfeld P, Sandborn W, et al. Systematic review: the effectiveness of budesonide for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509-17.
43. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of aziothioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45.
44. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000545.
45. Pearson DC, May GR, Fick GR, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000067.
46. Lemann M, Bouhnik Y, Colombel J, et al. Randomized, double-blind, placebo-controlled, multicentre, azathioprine withdrawal trial in Crohn's disease. Gastroenterology 2002;122:A23.
47. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on a controlled therapeutic trial. BMJ 1974;ii:627-30.
48. McGovern DPB, Travis SPL. Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol 2003;15:219-24.
49. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine-withdrawal in ulcerative colitis. BMJ 1992;305:20-22.
50. Lennard L, Gibson BE, Nicole T, et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577-9.
51. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
52. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9.
53. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for child-bearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17.
54. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
55. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
56. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
57. Fraser AG. Methotrexate: first or second-line immunomodulator? Eur J Gastroenterol Hepatol 2003;15:225-31.
58. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease (Cochrane Review). Cochrane Database Syst Rev 2003;(1):CD003459.
59. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
60. Hamilton RA, Kremer JM. Why intramuscular dosing may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
61. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150-6.
62. Hawthorne AB. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003;15:239-44.
63. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
64. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
65. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31.
66. Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion ciclosporin versus intravenous and soft gelatin capsule ciclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998;4:276-9.
67. Actis GC, Bresso F, Astegiano M, et al. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001;15:131-7.
68. Feagan BG. Cyclosporin has no proven role as a therapy for Crohn's disease. Inflamm Bowel Dis 1995;1:335-9.
69. Rutgeerts P, Van Assche G, Vermeire S. Optimising anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610.
70. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
71. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002;359:1541-9.
72. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
73. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
74. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
75. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
76. Margolin ML, Krumholz MP, Fochios SE, et al. Clinical trials in ulcerative colitis: II. Historical review. Am J Gastroenterol 1988;83:227-43.
77. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-76.
78. Marshal JK, Irvine EJ. Rectal corticosteroids versus alternative treatment in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81.
79. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of ulcerative colitis. Am J Gastro 1997;92:1867-71.
80. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multi-centred placebo-controlled trial. The US PENTASA Enema study group. Inflamm Bowel Dis 1998;4:79-83.
81. Allison MC, Vallance R. Prevalence of proximal faecal stasis in active ulcerative colitis. Gut 1991;32:179-82.
82. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13.
83. Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
84. Hawthorne AB, Travis SPL, and the BSG IBD Clinical Trials Network. Outcome of inpatient management of severe ulcerative colitis: a BSG IBD Clinical Trials Network Survey. Gut 2002;50:A16.
85. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210-12.
86. Daperno M, Sostegni R, Rocca R, et al. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 2002;16:7-12.
87. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine. Gut 1973;22:497-500.
88. Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow-release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double-blind placebo-controlled multicentre study. Gut 1998;42:195-9.
89. Ardizzone S, Molteni P, Bollani S, et al. Guidelines for the treatment of ulcerative colitis in remission. Eur J Gastroenterol & Hepatol 1997;9:836-41.
90. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001;15:1699-708.
91. Caprilli R, Viscido A, Guagnozzi D. Review article: biological agents in the treatment of Crohn's disease. Aliment Pharmacol Ther 2002;16:1579-90.
92. Sutherland LR, Singleton J, Sessions J, et al. Double-blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
93. Ferguson A, Glen M, Ghosh S. Crohn's disease: nutrition and nutritional therapy. Bailleres Clin Gastroenterol 1998;12:93-114.
94. Messori A, Trallori G, D'Alboisio G, et al. Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Scand J Gastroenterol 1996;31:267-72.
95. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterology Association Clinical practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology 2003;125:1508-30.
96. Ostro MJ, Greenberg GR, Jeejeebhoy KN. Total parenteral nutrition and complete bowel rest in the management of Crohn's disease. J Parenter Enteral Nutr 1985;9:280-7.
97. Witte AM, Veenendaal RA, Van Hogezand RA, et al. Crohn's disease of the upper gastrointestinal tract: the value of endoscopic examination. Scand J Gastroenterol Suppl 1998;225:100-5.
98. Couckuyt H, Gevers AM, Coremans G, et al. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective long term analysis. Gut 1995;36:577-80.
99. Lavy A. Triamcinolone improves outcome in Crohn's disease strictures. Dis Colon Rectum 1997;40:184-6.
100. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;109:643-8.
101. Camma C, Ciunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
102. Cottone M, Camma C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 2000;119:597.
103. Travis SPL, ed. Recent advances in immunomodulation in the treatment of inflammatory bowel disease: review in depth. Eur J Gastroenterol Hepatol 2003;15:215-48.
104. Shorthouse AJ. Abdominal surgery for Crohn's disease. Coloproctology 2000;2:55-62.
105. Karch LA, Bauer JJ, Gorfine SR, et al. Subtotal colectomy with Hartmann's pouch for inflammatory bowel disease. Dis Colon Rectum 1995;38:635-9.
106. McKee RF, Keenan RA, Munro A. Colectomy for acute colitis: is it safe to close the rectal stump? Int J Colorect Dis 1995;10:222-4.
107. Ng RLH, Davies AH, Grace RH, et al. Subcutaneous rectal stump closure after emergency subtotal colectomy. Br J Surg 1992;79:701-3.
108. Hallgren TA, Fasth SB, Oresland TO, et al. Ileal pouch anal function after endoanal mucosectomy and handsewn ileoanal anastomosis compared with stapled anastomosis without mucosectomy. Eur J Surg 1995;161:915-21.
109. Goodfellow PB, Wakefield SE, Anderson JA, et al. Predicting ileoanal pouch function. Coloproctalogy 2000;2:68-71.
110. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995;222:120-7.
111. Reilly WT, Pemberton JH, Wolff BG, et al. Randomised prospective trial comparing ileal pouch-anal anastomosis performed by excising the anal mucosa to ileal pouch-anal anastomosis performed by preserving the anal mucosa. Ann Surg 1997;225:666-7.
112. Leong AP, Londono-Schimmer EE, Phillips RK. Life-table analysis of stomal complications following ileostomy. Br J Surg 1994;81:727-9.
113. Khubchandani IT, Kontostolis SB. Outcome of ileorectal anastomosis in an inflammatory bowel disease surgery experience of three decades. Arch Surg 1994;129:866-9.
114. Lashner BA, Evans AA, Hanauer SB. Preoperative total porenteral nutrition for bowel resection in Crohn's disease. Dig Dis Sci 1989;34:741-6.
115. Andrews HA, Keighley MRB, Alexander-Williams J, et al. Strategy for management of distal ileal Crohn's disease. Br J Surg 1991;78:679-82.
116. Edwards CM, George BD, Jewell DP, et al. Role of a defunctioning stoma in the management of large bowel Crohn's disease. Br J Surg 2000;87:1063-6.
117. Makowiec F, Jehle EC, Starlinger M. Clinical course of perianal fistulas in Crohn's disease. Gut 1995;37:696-701.
118. Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn's fistulas. Dis Colon Rectum 1996;39:1039-43.
119. Yamamoto T, Bain IM, Connolly AB, et al. Gastroduodenal fistulas in Crohn's disease: clinical features and management. Dis Colon Rectum 1998;41:1287-92.
120. Fazio VW, Marchetti F, Church JM, et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomised controlled trial. Ann Surg 1996;224:563-73.
121. Yamamoto T, Bain IM, Allan RM, et al. Stapled functional end-to-end anastomosis vs sutured end-to-end anastomosis following ileocolonic resection in Crohn's disease. Scand J Gastroenterol 1999;34:708-13.
122. Stebbing JF, Jewell DP, Kettlewell MGW, et al. Long term results of recurrence and reoperation after strictureplasty for obstructive Crohn's disease. Br J Surg 1995;82:1471-4.
123. Cristoldi M, Sampietro GM, Danelli PG, et al. Long-term results and multivariate analysis of prognostic factors in 138 consecutive patients operated on for Crohn's disease using "bowel sparing" techniques. Am J Surg 2000;179:266-70.
124. Cameron JL, Hamilton SR, Coleman J, et al. Patterns of ileal recurrence in Crohn's disease. A prospective randomised study. Ann Surg 1992;215:546-52.
125. Travis SPL. Azathioprine for prevention of postoperative recurrence in Crohn's disease. Eur J Gastroenterol Hepatol 2001;13:1277-9.
126. Korelitz B, Hanauer S, Rutgeerts P, et al. Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology 1998;114:A1011.
127. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
128. Sandborn W, McLeod R, Jewell DP. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev 2001;(2):CD001176.
129. Shepherd NA, Jass JR, Duval I, et al. Restoration proctocolectomy with ileal reservoir: a pathological histochemical study of mucosal biopsy specimens. J Clin Pathol 1987;40:601-7.
130. Mimura T, Rizzello F, Helwig U, et al. Four week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-17.
131. Shen B, Achkar JP, Lashner BA, et al. A randomized trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-5.
132. Gionchetti P, Rizello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
133. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002;51(Suppl 5):V10-2.
134. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33.
135. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54.
136. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125:1311-19.
137. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9.
138. Katz JA, Pore G. Inflammatory bowel disease and pregnancy. Inflamm Bowel Dis 2001;7:146-57.
139. Nørgärd B, Fonager K, Pedersen L, et al. Birth outcome in women exposed to 5-aminosalicylic acid in pregnancy: a Danish cohort study. Gut 2003;52:243-7.
140. Burke A, Lichtenstein GR, Rombeau JL. Nutrition and ulcerative colitis. Baillieres Clin Gastroenterol 1997;11:153-74.
141. Gassull MA, Cabre E. Nutrition in inflammatory bowel disease. Curr Opin Nutr Metab Care 2001;4:561-9.
142. Chintapatla S, Scott NA. Intestinal failure in complex gastrointestinal fistulae. Nutrition 2002;18:991-6.
143. Zachos M, Tondeur M, Griffiths AM. Enterai nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001;(3):CD000542.
144. Fernadez-Benares F, Cabre E, Esteve-Comas M, et al. How effective is enteral nutrition in inducing remission in active Crohn's disease? A meta-analysis of the randomized cinical trials. J Parenter Enteral Nutr 1995;19:356-64.
145. Graham TO, Kandil HM. Nutritional factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:203-18.
146. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:307-21.
147. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000;46(Suppl 1):i1-8.
148. Loftus EV, Crowson CS, Sandborn WJ, et al. Long term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002;123:468-75.
149. Van Staa T-P, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003;125:1591-7.
150. Compston J. Osteoporosis in inflammatory bowel disease. Gut 2003;52:63-4.
151. Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004;53:251-5.
152. Nightingale AJ, Middleton W, Middleton SJ, et al. Evaluation of the effectiveness of a specialist nurse in the management of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;9:967-73.